Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

Sponsor
National Healthcare Group, Singapore (Other)
Overall Status
Completed
CT.gov ID
NCT01344044
Collaborator
Duke-NUS Graduate Medical School (Other), Agency for Science, Technology and Research (Other), Singapore Clinical Research Institute (Other)
192
1
3
64.4
3

Study Details

Study Description

Brief Summary

This study aims to examine the efficacy of a brain-computer interface system for the treatment of inattentive symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The investigators hypothesis is that children with ADHD receiving treatment with the BCI-based training will improve to a greater extent than the control group.

Additionally, the investigators are also conducting an fMRI study involving interested participants, to elucidate the neural mechanisms underlying any behavioural improvement. This is necessary to help the investigators gain a better picture of brain correlates related to ADHD and understand how the intervention can affect the brain.

Condition or Disease Intervention/Treatment Phase
  • Device: BCI
Phase 2/Phase 3

Detailed Description

This BCI study will involve 2 phases. The first phase is a preliminary study to test the safety and effectiveness of the novel BCI device which involves newly developed dry electrode sensors and intervention game. Twenty children, aged 6-12 and diagnosed with Inattentive or Combined subtype of ADHD will be recruited for the study. This open-label, experimental arm will go through 8 weeks of BCI intervention.

The second phase will be a randomized controlled trial involving 160 children. They will be randomized into the treatment or control arm. The treatment arm will receive 8 weeks of BCI intervention, similar to the experimental arm. The other group will serve as wait-list controls.

The fMRI trial aims to examine the underlying neural processes explaining any therapeutic effects that may be seen.

The study will enroll 70 children with ADHD, aged 6-12, who are participating in the main randomized controlled trial: 40 from the BrainpalTM intervention group and 30 from the control group; participants will undergo fMRI scan at Week 0 and 8 or Week 8 and 16. The study will recruit another 30 children aged 6-12 from the community as the healthy control group, who will undergo the same imaging procedure once. The scans will involve both functional and structural imaging.

Study Design

Study Type:
Interventional
Actual Enrollment :
192 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomised Controlled Trial of a Brain-Computer Interface Based Intervention for the Treatment of ADHD
Study Start Date :
Jan 1, 2011
Actual Primary Completion Date :
May 13, 2016
Actual Study Completion Date :
May 13, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: BCI treatment

BCI treatment will commence during the week of the Baseline.

Device: BCI
24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Other Names:
  • Brain-Computer Interface
  • Other: Wait-list control

    BCI treatment will commence 8 weeks after Baseline

    Device: BCI
    24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
    Other Names:
  • Brain-Computer Interface
  • Experimental: BCI pilot arm

    This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.

    Device: BCI
    24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
    Other Names:
  • Brain-Computer Interface
  • Outcome Measures

    Primary Outcome Measures

    1. Attention Deficit Hyperactivity Disorder Rating Scale (ADHD Rating Scale) 4th Edition [Week 0, 8, 20, 24]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Years to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • DSM-IV-TR criteria for ADHD, either the combined or inattentive subtype, based on the Diagnostic Interview Schedule for Children (CDISC; Schaffer et al., 2000)
    Exclusion Criteria:
    • Present or history of medical treatment with stimulant medication and Atomoxetine

    • Co-morbid severe psychiatric condition or known sensori-neural deficit e.g. complete blindness or deafness (such that they cannot play computer games)

    • History of epileptic seizures

    • Known Developmental Delay (i.e. IQ 70 and below)

    • Predominantly Hyperactive/impulsive subtype of ADHD (i.e. no predominant inattentive symptoms)

    • Present/history polyunsaturated fatty acids supplement intake (e.g. Omega-3 oil, flax seed oil, cod liver oil) in the past 3 months

    • Present/history of traditional Chinese medicine (TCM) prescribed for treatment of attention problems in the past 1 month

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Child Guidance Clinic, Institute of Mental Health Singapore Singapore

    Sponsors and Collaborators

    • National Healthcare Group, Singapore
    • Duke-NUS Graduate Medical School
    • Agency for Science, Technology and Research
    • Singapore Clinical Research Institute

    Investigators

    • Principal Investigator: Choon Guan Lim, Institute of Mental Health, Singapore

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lim Choon Guan, Dr, National Healthcare Group, Singapore
    ClinicalTrials.gov Identifier:
    NCT01344044
    Other Study ID Numbers:
    • DSRB Domain A/09/395
    First Posted:
    Apr 28, 2011
    Last Update Posted:
    Mar 30, 2017
    Last Verified:
    Mar 1, 2017
    Keywords provided by Lim Choon Guan, Dr, National Healthcare Group, Singapore
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 30, 2017